Curia Boosts Sterile API Manufacturing with $4M Investment
🕓 Estimated Reading Time: 4-5 minutes Overview Curia, a leading global contract research, development, and manufacturing organization (CRDMO), has announced a significant drug development investment of $4 million to bolster its sterile API manufacturing capabilities. This strategic capital injection is earmarked for its facility in Rensselaer, New York, and aims to enhance the company's capacity to produce active pharmaceutical ingredients (APIs), particularly high-potency APIs (HPAPIs) used in critical drug formulations. The move is a direct response to escalating client demand within the biopharmaceutical sector, signaling Curia's commitment to strengthening its role in the global pharmaceutical supply chain, according to a recent press release from the company. Background & Context The pharmaceutical industry relies heavily on a robust supply of high-quality active pharmaceutical ingredients. Sterile APIs are particularly crucial for drugs administered parenterally (e...